Nuclea Biotechnologies secures two additional patents advancing work in personalized medicine

Nuclea Biotechnologies, Inc., has secured two new US patents: US Patent No. 8,900,820 B2, covering gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors, and US Design Patent No. D718,800 S, covering the design of a lens mount.

For use in non-small cell lung cancer, the invention described in US 8,900,820 B2 provides protein and gene expression profiles that indicate whether a patient will be responsive to a specific therapeutic compound that is an EGFR-TK inhibitor. By gaining insight as to which patients will respond to certain treatments, physicians are able to determine alternative treatment plans for those who won’t respond to the EGFR-TK inhibitor.

US D718,800 S is for the design of a lens mount that in used in the detection process of the company’s diagnostic assays using its nanochip technology. Nuclea is currently working with the State University of New York’s (SUNY) College of Nanoscale Science & Engineering on a new high-throughput nanochip to accelerate the diagnosis and treatment of breast, colon, prostate and other cancers. Learn more about Nuclea Biotechnologies.